At least three biotech companies say they’ve received orders to stop their work related to a Biden administration initiative ...

British drugmaker AstraZeneca is rejoining the drug industry's major US lobbying group, PhRMA, roughly two years after ...

For the first time since the Trump administration's major staff cuts at the FDA this month, the agency publicly announced that the firings will lead to a long delay for what would otherwise be a ...

Fujifilm Diosynth Biotechnologies' bet on its North Carolina biologics facility is paying off, as Regeneron plans to shell ...

Paul Stoffels joined Galapagos to turn it around three years ago. But after a series of unsuccessful studies, pipeline changes and a bumpy quest into cell therapy, the Belgian biotech's turnaround ...

Invivyd secures $30M loan facility from Silicon Valley Bank in three $10M tranches, ahead of FDA discussions about Covid-19 antibody VYD2311 ...

Matter Bio, co-founded by George Church, partners with scientists to study longevity genes in centenarians and long-lived ...

Pharma companies stockpile drugs in US ahead of expected Trump tariffs, while execs warn of R&D cuts and manufacturing ...

Superpower raises $30M Series A led by Forerunner to expand health testing service offering blood biomarker analysis and app access for $499/year ...

The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry ...

Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid ...

AstraZeneca/Daiichi's Enhertu plus Perjeta shows better progression-free survival vs standard care in first-line HER2+ ...